NextGen Immuno Therapeutics
NextGen Immuno Therapeutics builds the future of immune diagnostics through AiResolve, an AI-powered scalable SaaS platform for precision medicine focused on the early detection and personalized treatment of immune diseases like cancer and autoimmune disorders.
Classification
Profile
Funding
Funding details not yet available.
Provides an AI-powered SaaS platform called AiResolve for the early detection and personalized treatment of immune diseases like cancer, autoimmune disorders, and Graft-versus-host disease.
Healthcare providers and pharmaceutical organizations in the DACH region requiring precision medicine solutions for immune diagnostics and personalized treatment protocols.
Operates as a scalable SaaS platform, likely charging subscription or usage-based fees for access to the AiResolve AI-powered diagnostic and treatment tools.
Information insufficient regarding specific sales motions like direct, PLG, or channel partners; likely B2B direct sales given the specialized medical nature.
Information insufficient regarding specific strategic allies, technology providers, or distribution partners involved in their ecosystem.
Primary costs likely involve AI model development, clinical data validation, platform scalability, and regulatory compliance for medical software in the DACH region.
The proprietary AiResolve AI technology, specialized immune disease data for training models, and the company's expertise in precision medicine and HealthTech.
Core operations include developing the AiResolve AI platform, validating algorithms for precision medicine, and scaling the SaaS infrastructure for early detection capabilities.
Information insufficient regarding specific acquisition or retention models; B2B HealthTech solutions typically involve dedicated account management or technical onboarding.
Competes in the immune diagnostics and precision medicine space; differentiates through its specific focus on AiResolve, an AI-powered scalable SaaS for early detection of complex immune diseases.
Addresses the need for accurate early detection of immune diseases and the challenge of delivering personalized treatment plans for conditions like cancer and autoimmune disorders.
- Regulatory Acceleration - pursue FDA Breakthrough Device designation to shorten time-to-market for high-impact oncology use cases
The AI-driven immune profiling claim is supported by a recent partnership announcement that highlights joint marketing and data acquisition, · NGIT’s focus on early detection and personalized therapy aligns with industry forecasts that the immunotherapy market will exceed $1.4 trill · The patent-pending status of core algorithms adds a defensible m
No investors recorded yet.